SYT1 and Alzheimer disease: Recent studies reported increased CSF Synaptotagmin-1 levels in both MCI and AD patients compared to healthy controls [90], indicating that Synaptotagmin-1 is a potential CSF biomarker of both AD and conversion from MCI to AD.